A 2002 piece published by A.M. Costei and a team of medical researchers from Toronto in the medical journal Archives of Pediatrics and Adolescent Medicine tited “Perinatal outcome following third trimester exposure to paroxetine.” further demonstrates possible adverse effects of in utero exposure to Paxil. (“Paroxetine” is the chemical name for Paxil, a selective serotonin reuptake inhibitor, or SSRI, for short.)
Studying “Fifty-five pregnant women counseled prospectively by the Motherisk program in Toronto, Ontario, regarding third-trimester exposure to paroxetine and their infants,” but after some exclusion, “A comparison group of 27 women using paroxetine during the first or second trimester and 27 women using nonteratogenic drugs were matched for maternal age, gravity, parity, social drug use, and nonteratogenic drug use.”
Results showed that “Of the 55 neonates exposed to paroxetine in late gestation, 12 had complications necessitating intensive treatment and prolonged hospitalization. The most prevalent clinical picture was respiratory distress (n = 9), followed by hypoglycemia (n = 2), and jaundice (n = 1).”
In the comparison group (control group), only 3 babies suffered similar symptoms. As such, statistics showed that “third-trimester exposure to paroxetine was associated with neonatal distress (odds ratio, 9.53; 95% confidence interval, 1.14-79.3)”, meaning babies exposed to Paxil were nearly 10 times as likely to have adverse perinatal outcomes.
If you or a loved one used Paxil and gave birth to a child with a congenital malformation, you may be entitled to significant financial compensation through a Paxil® birth defect lawsuit. For a free, no-obligation case consultation, contact our team of Paxil® birth defects lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve. Call today and see how we can help.
(855) 452 – 5529